ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Gastroprotective and therapeutic effects of emodin on rat model of diclofenac-induced gastric ulceration.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Topical ronomilast alone or combined with clobetasol ameliorates imiquimod-induced psoriasis in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Anthraquinone Derivative Rufigallol Protects Against Ethanol-Induced Gastric Damage via Modulation of PGEAntioxidants (Basel, Switzerland) · 2026Article
- Combining Diclofenac and Cannabidiol to Enhance the Antibacterial Capacity of Nonantibiotic Drugs Through Potentiation.International journal of molecular sciences · 2026Article
- Nephroprotective Effect of L-Carvone on a Mouse Model of LPS-Induced Sepsis-Associated Renal Injury via Regulation of TLR4/NF-κB/AP-1/IRF-3 and Nrf2/iNOS Molecular Signaling Cascades.Journal of Taibah University Medical Sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diclofenac, a commonly prescribed NSAID, is frequently associated with gastric ulcer development. Emodin, a natural anthraquinone derivative, exhibits robust anti-inflammatory and antioxidant properties that may offer gastroprotective benefits. This study aimed to evaluate the protective and therapeutic effects of emodin on diclofenac-induced gastric ulcers in rats. A total of 56 male Wistar rats were randomly divided into seven groups (n = 8 each): healthy control, pre-induction, post-induction, pre-emodin, post-emodin, pre-esomeprazole, and post-esomeprazole. Gastric ulcers were induced with diclofenac (100 mg/kg), and emodin (10 mg/kg) or esomeprazole (20 mg/kg) was administered orally for 14 days, either before or after ulcer induction. Pre- and post-treatment with emodin significantly reduced ulcer indices, preserved mucosal integrity, and improved gastric pH, PGE2, and COX-1 levels, while decreasing gastric juice volume, pepsin, asymmetric dimethylarginine (ADMA), and alpha-1 antitrypsin (α1ATP). Emodin also attenuated oxidative stress, enhanced antioxidant defenses, reduced IL-6, and increased IL-10. Notably, it promoted angiogenesis via elevated VEGF and HGF and normalized diclofenac-induced histological alterations, supporting tissue repair. Emodin demonstrates potent gastroprotective and therapeutic effects against diclofenac-induced ulcers by modulating oxidative, inflammatory, and angiogenic pathways, highlighting its potential as a natural alternative to standard anti-ulcer therapy.
Indexed as
Identifiers
41123635What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.